Cresco Labs (CRLBF) Depreciation & Amortization (CF) (2020 - 2026)
Cresco Labs' (CRLBF) quarterly Depreciation & Amortization (CF) came in at $12.2 million in Q1 2026, down 5.35% YoY from $12.9 million in Q1 2025, and up 13.53% on a QoQ basis from $10.8 million in Q4 2025.
Cresco Labs (CRLBF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $12.2 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 5.35% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.0 million (down 15.26% YoY) and the FY2025 annual result came in at $48.7 million, down 17.57% from the prior year.
- Depreciation & Amortization (CF) advanced to $12.2 million in Q1 2026, from $10.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $20.3 million in Q4 2023 to a low of $10.8 million in Q4 2025.
- A 5-year average of $13.8 million and a median of $13.3 million in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 33.72% — and 2024, when it plunged 31.35%.
- Tracing CRLBF's Depreciation & Amortization (CF) over 5 years: stood at $13.4 million in 2022, then surged by 51.19% to $20.3 million in 2023, then sank by 31.35% to $13.9 million in 2024, then dropped by 22.62% to $10.8 million in 2025, then increased by 13.53% to $12.2 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $12.2 million (Q1 2026), $10.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn | 12.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.22 Mn |
| Mar 31, 2026 | 12.22 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Sep 30, 2025 | 12.86 Mn |
| Sep 30, 2025 | 12.86 Mn |
| Jun 30, 2025 | 12.19 Mn |
| Jun 30, 2025 | 12.19 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Dec 31, 2024 | 13.90 Mn |
| Dec 31, 2024 | 13.90 Mn |
| Sep 30, 2024 | 14.93 Mn |
| Sep 30, 2024 | 14.93 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 20.25 Mn |
| Dec 31, 2023 | 20.25 Mn |